Cardiff Oncology (CRDF) EBIT Margin (2016 - 2025)
Cardiff Oncology (CRDF) has disclosed EBIT Margin for 15 consecutive years, with 3220.99% as the latest value for Q4 2025.
- Quarterly EBIT Margin rose 510484.0% to 3220.99% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 8256.32% through Dec 2025, down 114360.0% year-over-year, with the annual reading at 8256.32% for FY2025, 113319.0% down from the prior year.
- EBIT Margin hit 3220.99% in Q4 2025 for Cardiff Oncology, up from 9978.33% in the prior quarter.
- In the past five years, EBIT Margin ranged from a high of 3220.99% in Q4 2025 to a low of 14964.86% in Q1 2022.
- Historically, EBIT Margin has averaged 9207.82% across 5 years, with a median of 8231.52% in 2021.
- Biggest five-year swings in EBIT Margin: surged 918731bps in 2024 and later plummeted -786132bps in 2025.
- Year by year, EBIT Margin stood at 7162.41% in 2021, then dropped by -2bps to 7337.5% in 2022, then rose by 10bps to 6623.08% in 2023, then dropped by -26bps to 8325.83% in 2024, then soared by 61bps to 3220.99% in 2025.
- Business Quant data shows EBIT Margin for CRDF at 3220.99% in Q4 2025, 9978.33% in Q3 2025, and 12212.4% in Q2 2025.